Table 1 Characteristics of the study participants
Variable | CESC | Normal | Total | P-value | |||
|---|---|---|---|---|---|---|---|
306 | 3 | 309 | |||||
Age | Mean (IQR) | 47(39,57) | 55(48,62) | 0.44 a | |||
Sex | Female | 306(100.0%) | 3(100.0%) | 309(100.0%) | > 0.99 b | ||
Male | 0(0.0%) | 0(0.0%) | 0(0.0%) | ||||
Smoking | Yes | 263(85.9%) | 2(66.7%) | 265(85.8%) | 0.37 b | ||
No | 43(14.1%) | 1(33.3%) | 44(14.2%) | ||||
Pregnancy | Yes | 250(81.7%) | 2(66.7%) | 252(81.6%) | > 0.99 b | ||
No | 17(5.6%) | 0(0%) | 17(5.5%) | ||||
Unknown | 39(12.7%) | 1(33.3%) | 40(12.9%) | ||||
Grade | G1 | 18(5.9%) | |||||
G2 | 136(44.4%) | ||||||
G3 | 121(39.5%) | ||||||
G4 | 1(0.3%) | ||||||
GX | 30(9.8%) | ||||||
Primary tumor size | T1 | 140(45.8%) | |||||
T2 | 72(23.5%) | ||||||
T3 | 22(7.2%) | ||||||
T4 | 10(3.3%) | ||||||
TX | 62(20.3%) | ||||||
Lymph node status | N0 | 135(44.1%) | |||||
N1 | 58(19.0%) | ||||||
NX | 113(36.9%) | ||||||
Metastasis status | M0 | 135(44.1%) | |||||
M1 | 10(3.3%) | ||||||
MX | 161(52.6%) | ||||||
Tumor stage | I | 163(53.3%) | |||||
II | 70(22.9%) | ||||||
III | 46(15.0%) | ||||||
IV | 21(6.9%) | ||||||
X | 6(2.0%) | ||||||
Chemotherapy | Complete response | Partial response | Unknown | ||||
Cisplatin | 64(58.2%) | 18(16.4%) | 28(25.5%) | 110 | |||
Carboplatin | 0(0%) | 4(66.7%) | 2(33.3%) | 6 | |||
Others | 12(50.0%) | 5(20.8%) | 7(29.2%) | 24 | |||
Unknown | 68(41.0%) | 7(10.6%) | 91(54.8%) | 166 | |||